Loading company
HCW Biologics Inc.
HCWB · Nasdaq · ·
$1.78-2.5%Sep 29 close
- 1M
- -48.4%
- 6M
- -1.1%
- 1Y
- -92.2%
- 5Y
- -99.8%
HCWB · Nasdaq · ·
$1.78-2.5%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $121.7K | $6.6K | +1,758.47% |
| Profit | -$5.2M | -$1.9M | -170.74% |
| Profit per share | $1.39 | -$0.20 | +795.00% |
| Free Cash Flow | -$3.4M | -$2.9M | -13.81% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
HCW Biologics Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs, including its commercial-ready reagents to be used in the production of immunotherapeutics for cancer and infectious diseases. To date, the Company has entered into two licensing agreements in which it has licensed exclusive, worldwide rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from HCW Biologics Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.